Solarea Bio

Solarea Bio innovates microbial solutions for human health, focusing on aging-related conditions. The company develops products addressing dietary needs related to rheumatoid arthritis, psoriatic arthritis, and other inflammatory conditions associated with aging, leveraging microbiome science to advance health outcomes. Founded in 2017 and headquartered in Cambridge, United States, Solarea Bio has raised approximately $37.2M in Series B funding from investors including Illumina, Bold Capital Partners, Viking Global Investors, S2G Investments, Joyance Partners, and Rising Tide Fund. The company combines microbiome research with nutritional science to develop bioactive products that modulate the gut microbiome for therapeutic benefit, addressing the growing intersection of nutrition and medicine for aging populations seeking to maintain mobility and quality of life through microbiome-targeted interventions.